Home › Funds › Opaleye Management Inc. › JBIO
Opaleye Management Inc. position in JBIO
JADE BIOSCIENCES INC · Health Care
Opaleye Management Inc. reported holding 145,000 shares of JBIO (JADE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$3.2M, representing 0.29% of its reported portfolio and ranking #42 among its reported holdings. Opaleye Management Inc. has disclosed JBIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Opaleye Management Inc.'s JBIO position evolved
Opaleye Management Inc. first disclosed a stake in JBIO in Q4 2025 at 427,608 shares (US$6.6M). Across 3 filings, Opaleye Management Inc. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 145,000 shares valued at US$3.2M — a reduction of -282,608 shares quarter over quarter.. Notable position changes include a 66% trim in Q2 2026 (shares fell 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 427.61K | $6.60M | New |
| Q1 2026 | 427.61K | $6.01M | Hold |
| Q2 2026 | 145.00K | $3.22M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JBIO and 13F data
JBIO (JADE BIOSCIENCES INC) is a Health Care company. 106 other funds we track also report a position in JBIO — the largest reported positions include Fairmount Funds Management LLC (US$101.2M), RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JBIO
- Fairmount Funds Management LLC 4.55M sh · $101.18M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 3.67M sh · $81.57M · Q2 2026
- Venrock Adviser, LLC 3.22M sh · $71.56M · Q2 2026
- Bellevue Group AG 3.06M sh · $67.95M · Q2 2026
- Paradigm Biocapital Advisors LP 2.86M sh · $63.49M · Q2 2026
- Avidity Partners Management LP 1.70M sh · $37.79M · Q2 2026
- Remedium Capital Partners, LLC 1.58M sh · $35.06M · Q2 2026
- Soleus Capital Management, L.P. 1.55M sh · $34.46M · Q2 2026
- BAKER BROS. ADVISORS LP 1.23M sh · $27.34M · Q2 2026
- Logos Global Management LP 1.12M sh · $25.00M · Q2 2026
- Versant Venture Management, LLC 991.78K sh · $22.04M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 986.76K sh · $21.93M · Q2 2026
More on Opaleye Management Inc.
FAQ
How long has Opaleye Management Inc. held JBIO?
Opaleye Management Inc. has disclosed JBIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Opaleye Management Inc.'s current position in JBIO?
As of Q2 2026, Opaleye Management Inc. holds 145.00K shares of JBIO (JADE BIOSCIENCES INC), valued at $3.22M, representing 0.29% of its reported portfolio and ranking #42.
Has Opaleye Management Inc. been buying or selling JBIO?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. reduced its position in JBIO.
Which other funds hold JBIO?
Other major institutional holders of JBIO include Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, among 106 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.